Drug interactions
Secukinumab + Tisagenlecleucel
Severity: Moderate
Secukinumab and Tisagenlecleucel: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tisagenlecleucel is a CAR T-cell therapy given after lymphodepleting chemotherapy and causes prolonged immune compromise. Immunomodulating biologics such as secukinumab could add to infection risk and might theoretically interfere with CAR T-cell expansion or function. Clinical data on the combination are lacking.
What this interaction means in plain words
Secukinumab and Tisagenlecleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Secukinumab belongs to Miscellaneous; Tisagenlecleucel belongs to Oncology.
Why it happens
Additive immunosuppression; IL-17A blockade could theoretically affect CAR T-cell activity, but the mechanism is not established.
What to do
Hold secukinumab around lymphodepletion and CAR T infusion unless clearly needed, and resume only when the oncology team judges it safe. Monitor for infections.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Secukinumab and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Secukinumab
- Adenovirus types 4 and 7 live + Secukinumab Major
- Bcg vaccine live + Secukinumab Major
- Influenza virus vaccine quadrivalent intranasal + Secukinumab Major
- Measles mumps and rubella vaccine live + Secukinumab Major
- Measles mumps and rubella vaccine + Secukinumab Major
- Measles mumps rubella and varicella vaccine live + Secukinumab Major
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Secukinumab with Tisagenlecleucel?
MediHelp rates the interaction as moderate. Secukinumab and Tisagenlecleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Tisagenlecleucel is a CAR T-cell therapy given after lymphodepleting chemotherapy and causes prolonged immune compromise. Immunomodulating biologics such as secukinumab could add to infection risk and might theoretically interfere with CAR T-cell expansion or function. Clinical data on the combination are lacking.
How serious is the interaction between Secukinumab and Tisagenlecleucel?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Hold secukinumab around lymphodepletion and CAR T infusion unless clearly needed, and resume only when the oncology team judges it safe. Monitor for infections.
What other medicines interact with Secukinumab?
MediHelp also lists interactions of Secukinumab with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Influenza virus vaccine quadrivalent intranasal. The full list is on the Secukinumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
